This Luveris market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth observed in the historical period can be attributed to factors such as the increasing number of fertility clinics, higher healthcare expenditure, the rise in the use of personalized medicine, a growing prevalence of obesity, and increasing urbanization.
The expected growth in the forecast period is driven by factors such as the rising prevalence of infertility in both men and women, an increase in hormonal disorders, a growing incidence of obesity, higher investments in fertility research, and the expansion of genetic screening. Key trends for the forecast period include technological advancements, developments in assisted reproductive technology, improvements in hormone therapy, personalized medicine, and the integration of artificial intelligence.
The rising infertility rates are expected to significantly drive the growth of the luveris market. Infertility rates refer to the percentage of individuals or couples who are unable to conceive after a year of trying, and these rates are increasing due to factors such as delayed childbearing, lifestyle choices, environmental pollutants, and underlying health conditions. Luveris is used to treat infertility in women with low luteinizing hormone (LH) levels, by stimulating ovulation and promoting egg development in the ovaries. For instance, the Human Fertilization and Embryology Authority (HFEA) in the UK reported that in 2022, approximately 52,500 patients underwent in vitro fertilization (IVF), a rise of 11% from 2019. This increase in IVF cycles and fertility treatments correlates with rising infertility rates, which will consequently boost the demand for treatments such as luveris.
The expanding healthcare infrastructure is key factor expected to propel the growth of the luveris market. Healthcare infrastructure includes essential facilities, equipment, healthcare workers, and systems needed to deliver healthcare services. As healthcare infrastructure grows to meet the increasing demand for medical services, including fertility treatments, it will improve access to advanced reproductive care. This development is particularly important for the infertility treatment market, which requires specialized medical centers offering innovative therapies. For example, in May 2023, the UK government announced an investment of $25.33 billion (£20 billion) in its New Hospital Programme, which will lead to the construction of 40 new hospitals by 2030. Such investments in healthcare infrastructure will positively impact the luveris market by improving access to fertility treatments.
A key trend driving the growth of the luveris market is the strategic investment in research and development (R&D) to create novel medicines and treatments. Strategic investments allow companies to expand market share, enhance capabilities, and achieve long-term business goals. For instance, Merck KGaA, a Germany-based company, invested $316 million (€300 million) in a new research facility in Darmstadt, Germany, to advance research on biotechnology, including antibody production, mRNA applications, and other biotechnological products. This focus on innovative solutions is crucial for developing new fertility treatments, contributing to the growth of the Luveris market by offering more effective and advanced options for infertility management.
The key company operating in the luveris market is Merck KGaA.
North America was the largest region in the luveris market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in luveris report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the luveris market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Luveris (lutropin alfa) is a synthetic version of luteinizing hormone used in fertility treatments for women with severe LH deficiency or those undergoing assisted reproductive technologies, such as in vitro fertilization (IVF). It functions by mimicking the natural hormone LH, which stimulates the development of ovarian follicles and ovulation, typically in combination with follicle-stimulating hormone (FSH). Administered through subcutaneous injection, Luveris is crucial in helping women achieve successful ovulation and pregnancy outcomes, under the guidance of a healthcare professional.
Primary types of Luveris formulations include injectable forms, such as intravenous (IV) injections and pre-filled syringes. The injectable formulation of Luveris is administered directly into the bloodstream via an intravenous injection. It is used to treat conditions such as hypogonadotropic hypogonadism, ovulation induction, and assisted reproductive technologies. The medication can be administered through subcutaneous or intramuscular injection routes. Various patient groups, including adult females, adult males, and couples undergoing fertility treatments, use Luveris. It is available through hospitals, fertility clinics, specialty pharmacies, and home healthcare providers.
The luveris market research report is one of a series of new reports that provides luveris market statistics, including luveris industry global market size, regional shares, competitors with a luveris market share, detailed luveris market segments, market trends and opportunities, and any further data you may need to thrive in the luveris industry. This luveris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The luveris market consists of sales of follitropin alfa, menotropins, progesterone and follitropin beta. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth observed in the historical period can be attributed to factors such as the increasing number of fertility clinics, higher healthcare expenditure, the rise in the use of personalized medicine, a growing prevalence of obesity, and increasing urbanization.
The expected growth in the forecast period is driven by factors such as the rising prevalence of infertility in both men and women, an increase in hormonal disorders, a growing incidence of obesity, higher investments in fertility research, and the expansion of genetic screening. Key trends for the forecast period include technological advancements, developments in assisted reproductive technology, improvements in hormone therapy, personalized medicine, and the integration of artificial intelligence.
The rising infertility rates are expected to significantly drive the growth of the luveris market. Infertility rates refer to the percentage of individuals or couples who are unable to conceive after a year of trying, and these rates are increasing due to factors such as delayed childbearing, lifestyle choices, environmental pollutants, and underlying health conditions. Luveris is used to treat infertility in women with low luteinizing hormone (LH) levels, by stimulating ovulation and promoting egg development in the ovaries. For instance, the Human Fertilization and Embryology Authority (HFEA) in the UK reported that in 2022, approximately 52,500 patients underwent in vitro fertilization (IVF), a rise of 11% from 2019. This increase in IVF cycles and fertility treatments correlates with rising infertility rates, which will consequently boost the demand for treatments such as luveris.
The expanding healthcare infrastructure is key factor expected to propel the growth of the luveris market. Healthcare infrastructure includes essential facilities, equipment, healthcare workers, and systems needed to deliver healthcare services. As healthcare infrastructure grows to meet the increasing demand for medical services, including fertility treatments, it will improve access to advanced reproductive care. This development is particularly important for the infertility treatment market, which requires specialized medical centers offering innovative therapies. For example, in May 2023, the UK government announced an investment of $25.33 billion (£20 billion) in its New Hospital Programme, which will lead to the construction of 40 new hospitals by 2030. Such investments in healthcare infrastructure will positively impact the luveris market by improving access to fertility treatments.
A key trend driving the growth of the luveris market is the strategic investment in research and development (R&D) to create novel medicines and treatments. Strategic investments allow companies to expand market share, enhance capabilities, and achieve long-term business goals. For instance, Merck KGaA, a Germany-based company, invested $316 million (€300 million) in a new research facility in Darmstadt, Germany, to advance research on biotechnology, including antibody production, mRNA applications, and other biotechnological products. This focus on innovative solutions is crucial for developing new fertility treatments, contributing to the growth of the Luveris market by offering more effective and advanced options for infertility management.
The key company operating in the luveris market is Merck KGaA.
North America was the largest region in the luveris market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in luveris report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the luveris market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Luveris (lutropin alfa) is a synthetic version of luteinizing hormone used in fertility treatments for women with severe LH deficiency or those undergoing assisted reproductive technologies, such as in vitro fertilization (IVF). It functions by mimicking the natural hormone LH, which stimulates the development of ovarian follicles and ovulation, typically in combination with follicle-stimulating hormone (FSH). Administered through subcutaneous injection, Luveris is crucial in helping women achieve successful ovulation and pregnancy outcomes, under the guidance of a healthcare professional.
Primary types of Luveris formulations include injectable forms, such as intravenous (IV) injections and pre-filled syringes. The injectable formulation of Luveris is administered directly into the bloodstream via an intravenous injection. It is used to treat conditions such as hypogonadotropic hypogonadism, ovulation induction, and assisted reproductive technologies. The medication can be administered through subcutaneous or intramuscular injection routes. Various patient groups, including adult females, adult males, and couples undergoing fertility treatments, use Luveris. It is available through hospitals, fertility clinics, specialty pharmacies, and home healthcare providers.
The luveris market research report is one of a series of new reports that provides luveris market statistics, including luveris industry global market size, regional shares, competitors with a luveris market share, detailed luveris market segments, market trends and opportunities, and any further data you may need to thrive in the luveris industry. This luveris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The luveris market consists of sales of follitropin alfa, menotropins, progesterone and follitropin beta. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Luveris Market Characteristics4. Luveris Market Trends and Strategies5. Luveris Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Luveris Pricing Analysis & Forecasts30. Global Luveris Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Luveris Market32. Recent Developments in the Luveris Market
3. Luveris Market Biologic Drug Characteristics
6. Global Luveris Growth Analysis and Strategic Analysis Framework
8. Luveris Market Segmentation
9. Global Luveris Epidemiology of Clinical Indications
10. Luveris Market Regional and Country Analysis
11. Asia-Pacific Luveris Market
12. China Luveris Market
13. India Luveris Market
14. Japan Luveris Market
15. Australia Luveris Market
16. South Korea Luveris Market
17. Western Europe Luveris Market
18. UK Luveris Market
19. Germany Luveris Market
20. France Luveris Market
21. Eastern Europe Luveris Market
22. North America Luveris Market
23. USA Luveris Market
24. Canada Luveris Market
25. South America Luveris Market
26. Middle East Luveris Market
27. Africa Luveris Market
28. Luveris Market Competitive Landscape and Company Profiles
29. Global Luveris Market Pipeline Analysis
33. Luveris Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Luveris Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on luveris market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for luveris? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The luveris market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Formulation: Injectable Formulation (Intravenous); Pre-Filled Syringes2)by Indication: Treatment of Hypogonadotropic Hypogonadism; Ovulation Induction; Assisted Reproductive Technology
3) by Route of Administration: Subcutaneous Injection; Intramuscular Injection
4) by Patient Demographics: Adult Female Patients; Adult Male Patients; Couples Undergoing Fertility Treatments
5) by End User: Hospitals; Fertility Clinics; Specialty Pharmacies; Home Healthcare Providers
Key Companies Mentioned: Merck KGaA
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Merck KGaA
